Ordering Information
Product Images
Rat Visfatin RIA
Description:
Rat Visfatin RIA
Background Information:
Because of the increase in the incidence of metabolic syndrome, especially diabetes type 2 in younger individuals, clarifying the role that visfatin plays may help to better understand the pathogenesis of these disorders. Millipore’s new Rat Visfatin RIA kit is a quality tool to assist researchers in developing therapeutics for the treatment, and possibly the prevention of diseases associated with metabolic syndrome.
Visceral fat accumulation is associated with many metabolic syndrome disorders, including glucose intolerance, chronic inflammatory response, hypertension and coronary artery disease. While adipose tissue is responsible for the expression and secretion of many adipokines, visfatin (also known pre-B cell enhancing factor – PBEF – and as Nampt) demonstrates a preferential expression in visceral fat. Previous studies seemed to indicate that visfatin expression is increased in the visceral fat of obese individuals; however, no direct link has been confirmed connecting plasma levels of visfatin to insulin insensitivity. Recent investigations have concluded that visfatin is the rate-limiting component in NAD biosynthesis and is critical for pancreatic -cell function, suggesting that visfatin plays a vital role in the regulation of glucose homeostasis. Visfatin-deficient mice show significant decreases in NAD biosynthesis and insulin secretion in response to glucose. Further study of visfatin may provide important clues to developing preventative and/or therapeutic compounds for metabolic complications, such as diabetes type 2.
Visceral fat accumulation is associated with many metabolic syndrome disorders, including glucose intolerance, chronic inflammatory response, hypertension and coronary artery disease. While adipose tissue is responsible for the expression and secretion of many adipokines, visfatin (also known pre-B cell enhancing factor – PBEF – and as Nampt) demonstrates a preferential expression in visceral fat. Previous studies seemed to indicate that visfatin expression is increased in the visceral fat of obese individuals; however, no direct link has been confirmed connecting plasma levels of visfatin to insulin insensitivity. Recent investigations have concluded that visfatin is the rate-limiting component in NAD biosynthesis and is critical for pancreatic -cell function, suggesting that visfatin plays a vital role in the regulation of glucose homeostasis. Visfatin-deficient mice show significant decreases in NAD biosynthesis and insulin secretion in response to glucose. Further study of visfatin may provide important clues to developing preventative and/or therapeutic compounds for metabolic complications, such as diabetes type 2.
Key Applications:
Radioimmunoassay
Application Notes:
Two-day disequilibrium assay incubate at 4°C; Sample volume: 100 µL serum, plasma or tissue culture supernant
Species Reactivity:
Rat
Kit or Assay Type:
- Endocrine Kits
- Radioimmunoassays (RIA)
Therapeutic Areas:
- Diabetes Type 2
- Obesity
- Cardiovascular Disease
- Chronic Inflammatory Disease
Linearity of Dilution:
Please contact Technical Service for this information
Label:
125I-Rat Visfatin
Sensitivity:
0.78 ng/mL (Minimum Detectable Concentrations)
Precision, %:
- Intra-assay: 3 - 5%
- Inter-assay: 9 - 11%
Accuracy:
71-73% (in serum samples)
Detection Methods:
125I
Performance:
- ED80 = 2.7 ± 0.24 ng/mL
- ED50= 8.2 ± 0.71 ng/mL
- ED20= 26.5 ± 2.28 ng/mL
Standard Curve Range:
0.78 - 50 ng/mL
Specificity:
There was 6% cross-reactivity with Mouse Visfatin, and 0.1% cross-reactivity with Human Visfatin. No detectable cross-reactivity was observed with Rat Insulin, Rat C-peptide, Rat Leptin, or Glucagon.